Véronique Suttels

Véronique Suttels


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
VSVéronique Suttels
Véronique Suttels
MSMathias Van Singer
Mathias Van Singer
LCLauren Clack
Lauren Clack
CPCatherine Plüss-Suard
Catherine Plüss-Suard
ANAnne Niquille
Anne Niquille
NBNoémie Boillat-Blanco
Noémie Boillat-Blanco
Antimicrobial resistance (AMR) is directly driven by inappropriate use of antibiotics. Although the majority of antibiotics (an estimated 80%) are consumed in primary care settings, antimicrobial stewardship (AMS) activities in primary care remain underdeveloped and factors influencing their implementation are poorly understood. This can result in promising stewardship activities having little-to-no real-world impact. With this narrative review, we aim to identify and summarize peer-reviewed literature reporting on (1) the nature and impact of AMS interventions in primary care and (2) the individual and contextual factors influencing their implementation. Reported activities included AMS at different contextual levels (individual, collective and policy). AMS activities being often combined, it is difficult to evaluate them as stand-alone interventions. While some important individual and contextual factors were reported (difficulty to reach physicians leading to a low uptake of interventions, tight workflow of physicians requiring implementation of flexible and brief interventions and AMS as a unique opportunity to strengthen physician-patients relationship), this review identified a paucity of information in the literature about the factors that support or hinder implementation of AMS in primary care settings. In conclusion, identifying multilevel barriers and facilitators for AMS uptake is an essential step to explore before implementing primary care AMS interventions.

8 July 2022 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
VSVéronique Suttels
Véronique Suttels
JTJacques D Du Toit
Jacques D Du Toit
AFArnauld Fiogbé
Arnauld Fiogbé
AWAblo Prudence Wachinou
Ablo Prudence Wachinou
BGBrice Guendehou
Brice Guendehou
MHMary Anne Hartley
Mary Anne Hartley
Point-of-care ultrasound (POCUS) is an increasingly accessible skill, allowing for the decentralization of its use to nonspecialist healthcare workers to guide routine clinical decision-making. The advent of ultrasound-on-a-chip has transformed the technology into a portable mobile health device. Because of its high sensitivity to detect small consolidations, pleural effusions, and subpleural nodules, POCUS has recently been proposed as a sputum-free likely triage tool for tuberculosis (TB). To make an objective assessment of the potential and limitations of POCUS in routine TB management, we present a Strengths, Weaknesses, Opportunities and Threats (SWOT) analysis based on a review of the relevant literature and focusing on Sub-Saharan Africa (SSA). We identified numerous strengths and opportunities of POCUS for TB management, e.g., accessible, affordable, easy to use and maintain, expedited diagnosis, extrapulmonary TB detection, safer pleural/pericardial puncture, use in children/pregnant women/people living with HIV, targeted screening of TB contacts, monitoring TB sequelae, and creating artificial intelligence decision support. Weaknesses and external threats such as operator dependency, lack of visualization of central lung pathology, poor specificity, lack of impact assessments and data from SSA must be taken into consideration to ensure that the potential of the technology can be fully realized in research as in practice.

21 April 2022 in JAC-Antimicrobial Resistance
Verified
Journal Article
Open access
PDF file
VSVéronique Suttels
Véronique Suttels
PAPascal André
Pascal André
YTYann Thoma
Yann Thoma
FVFrançois Veuve
François Veuve
LDLaurent Arthur Decosterd
Laurent Arthur Decosterd
TBThierry Buclin
Thierry Buclin
To describe the therapeutic drug monitoring (TDM) of cefepime in non-critically ill adults and compare four different ways of dosing: conventional table-based; empirically adjusted following TDM; individualized based on a population pharmacokinetic (PopPK) model without TDM; and TDM-adjusted with a Bayesian approach integrating TDM and PopPK. We conducted a retrospective study in a tertiary centre to examine the current practice of TDM and to evaluate the potential for improvement by PopPK-based software individualization. The prediction of trough concentrations and the total daily doses (TDD) prescribed according to each approach were compared by calculating the mean logarithmic bias and the root mean squared error, complemented by linear regression and variance analysis. Among 168 trough concentrations in 119 patients (median: 12 mg/L), 38.6% of measurements exceeded 15 mg/L, the reported threshold for neurotoxicity. Nine patients developed neurotoxicity. The prediction performance of PopPK alone for trough concentrations was moderate, but clearly improved after integration of TDM. Accordingly, TDD were significantly lower for a priori PopPK-based dosage (mean: 2907 mg/24 h) compared with actual table-based dosage (4625 mg/24 h, P < 0.001). They were also lower for a posteriori dosage based on PopPK and TDM (3377 mg/24 h) compared with actual dosage after empirical TDM (4233 mg/24 h, P < 0.001), as model-based adjustment privileged more frequent administrations. Our observations support routine TDM of cefepime to prevent overdosing and subsequent toxicity in the non-critically ill. Software-based individualization seems promising to optimize the benefits of TDM, but has little potential to replace it.

26 June 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
VSVéronique Suttels
Véronique Suttels
SCSofia Guedes Da Costa
Sofia Guedes Da Costa
EGElena Garcia
Elena Garcia
TBThomas Brahier
Thomas Brahier
MHMary-Anne Hartley
Mary-Anne Hartley
NBNoémie Boillat-Blanco
Noémie Boillat-Blanco
Objectives Owing to its ease-of-use and excellent diagnostic performance for the assessment of respiratory symptoms, point-of-care lung ultrasound (POC-LUS) has emerged as an attractive skill in resource-low settings, where limited access to specialist care and inconsistent radiology services erode health equity. To narrow down the research to practice gap, this study aims to gain in-depth insights in the perceptions on POC-LUS and computer-assisted POC-LUS for the diagnosis of lower respiratory tract infections (LRTIs) in a low-income and middle-income country (LMIC) of sub-Saharan Africa. Design and setting Qualitative study using face-to-face semi-structured interviews with three pneumologists and five general physicians in a tertiary centre for pneumology and tuberculosis in Benin, West Africa. The center hosts a prospective cohort study on the diagnostic performance of POC-LUS for LRTI. In this context, all participants started a POC-LUS training programme 6 months before the current study. Transcripts were coded by the interviewer, checked for intercoder reliability by an independent psychologist, compared and thematically summarised according to grounded theory methods. Results Various barriers− and facilitators+ to POC-LUS implementation were identified related to four principal categories: (1) hospital setting (eg, lack of resources for device renewal or maintenance−, need for POC tests+), (2) physician’s perceptions (eg, lack of opportunity to practice−, willingness to appropriate the technique+), (3) tool characteristics (eg, unclear lifespan−, expedited diagnosis+) and (4) patient’s experience (no analogous image to keep−, reduction in costs+). Furthermore, all interviewees had positive attitudes towards computer-assisted POC-LUS. Conclusions There is a clear need for POC affordable lung imaging techniques in LMIC and physicians are willing to implement POC-LUS to optimise the diagnostic approach of LRTI with an affordable tool. Successful integration of POC-LUS into clinical routine will require adequate responses to local challenges related to the lack of available maintenance resources and limited opportunity to supervised practice for physicians.

8 September 2015 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
VSVéronique Suttels
Véronique Suttels
EFEric Florence
Eric Florence
JLJohn Leys
John Leys
MVMarc Vekemans
Marc Vekemans
JEJef Van Den Ende
Jef Van Den Ende
CKChris Kenyon
Chris Kenyon
We present what we believe to be the first case in the literature of rhabdomyolysis-induced renal failure caused by a probable drug interaction between elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) and pravastatin/fenofibrate. A 68-year old Caucasian man presented with progressive pain in both legs two weeks after commencing treatment with EVG/COBI/FTC/TDF. He was found to have biochemical evidence of rhabdomyolysis and acute renal failure. We emphasize the need for post marketing surveillance of adverse effects of new products. Pharmacokinetic studies are necessary to investigate the levels of pravastatin in patients taking COBI and fenofibrate with and without other comorbidities. Meanwhile, we suggest that creatine kinase levels should be monitored and patients advised to report myalgias when using concomitant EVG/COBI/FTC/TDF and pravastatin/fenofibrate. This case serves as an important reminder to use estimated glomerular filtration rates rather than serum creatinine levels when choosing new medications. If potentially nephrotoxic combinations are started in patients with borderline estimated glomerular filtration rates, it may be prudent to check these filtration rates more frequently than usual. In patients with reduced estimated glomerular filtration rates, potentially nephrotoxic combinations should be avoided wherever possible.

3 April 2024 in Research Square
Verified
Preprint
Open access
PDF file
ZCZeming Chen
Zeming Chen
ARAngelika Romanou
Angelika Romanou
AHAlejandro Hernández-Cano
Alejandro Hernández-Cano
BABadr Alkhamissi
Badr Alkhamissi
KMKyle Matoba
Kyle Matoba
ABAntoine Bosselut
Antoine Bosselut
Large language and multimodal models (LLMs and LMMs) will transform access to medical knowledge and clinical decision support. However, the current leading systems fall short of this promise, as they are either limited in scale, which restricts their capabilities, closed-source, which limits the extensions and scrutiny that can be applied to them, or not sufficiently adapted to clinical settings, which inhibits their practical use. In this work, we democratize large-scale medical AI systems by developing MEDITRON: a suite of open-source LLMs and LMMs with 7B and 70B parameters adapted to the medical domain. MEDITRON extends pretraining on a comprehensively curated medical corpus that includes biomedical literature and internationally recognized clinical practice guidelines. Evaluations using standard medical reasoning benchmarks show significant improvements over all current open-access models and several state-of-the-art commercial LLMs that are orders of magnitude larger, more expensive to host, and closed-source. Enhanced with visual processing capabilities, our MEDITRON-V model also outperforms all open-access models and much larger closed-source models on multimodal reasoning tasks for various biomedical imaging modalities. Beyond traditional benchmarks, we also create a novel and physician-driven adversarial question dataset grounded in real-world clinical settings, and a comprehensive 17-metric evaluation rubric to assess alignment and contextualization to real-world clinical practice. Applying this framework to MEDITRON-70B's responses, sixteen independent physicians found a high level of alignment across all metrics, including medical accuracy, safety, fairness, communication, and interpretation. The MEDITRON suite is a significant step forward in closing the technological gap between closed- and open-source medical foundation models. By releasing our methodologies, models, and real-world clinical practice benchmarks, we aim to drive the open-source development of more capable, representative, accessible, and transparent medical AI assistants.